Prognostic Significance of CDK1 Expression in Diffuse Large B-Cell Lymphoma

Abstract

Abstract Objective This study delves into the clinical implications and expression of CDK1 in diffuse large B-cell lymphoma (DLBCL). Methods Gene expression information from healthy subjects was sourced from the Genotype-Tissue Expression (GTEx) repository. Clinical details and survival statistics for DLBCL patients came from the Gene Expression Omnibus (GEO) archive (GSE10846). Patients were categorized based on CDK1 expression levels, and differences in clinical outcomes between the groups were examined. Univariate and multivariate Cox regression analyses were employed to ascertain whether CDK1 independently predicts DLBCL prognosis. The protein expression of CDK1 was gauged using immunohistochemistry. Additionally, we investigated the outcome of CDK1 inhibition on DLBCL cell growth and cell death using Cell Counting Kit-8 (CCK-8) and flow cytometry. Results In the control group, CDK1 was predominantly observed in the hematopoietic and reproductive systems. CDK1 levels in DLBCL patients were notably elevated compared to controls. Significant differences were noted in the LDH ratio and overall survival based on CDK1 expression. Statistical analyses confirmed CDK1 as an independent predictor of DLBCL outcomes. Elevated CDK1 protein was observed in a significant number of DLBCL samples, contrasting with normal lymph node samples from individuals without lymphoma. An inhibitor, Ro-3306, curtailed DLBCL cell growth and enhanced cell death in vitro. Conclusion Elevated CDK1 levels correlate with poor prognosis in DLBCL.